Drug Database
AL

alternaria allergen SLIT

✓ Approved

HAL Allergy Group · therapeutic agent

What is alternaria allergen SLIT?

alternaria allergen SLIT is a therapeutic agent developed by HAL Allergy Group. It is approved for therapeutic indications via oral (po) or sublingual (sl)/oral transmucosal.

Drug Profile

CompanyHAL Allergy Group
RouteOral (PO), Sublingual (SL)/Oral Transmucosal
StatusApproved
Sources: ClinicalTrials.gov, HAL Allergy Group

Therapeutic Indications

alternaria allergen SLIT is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Immune system disordersHypersensitivity✓ Approved

Related Research Articles

PubMedBMC microbiology2026-05-24

Morphogenetic identification and enzymatic determination of local isolate fungi associated with mosquitoes at Assiut Governorate.

Morsy Sina M SM, Abdel-Galil Farouk A FA, Farghal Ahmed I A AIA, Abdel-Nasser Mohamed A MA et al.

Mosquitoes pose a significant threat as vectors for numerous human and animal diseases, particularly in tropical and subtropical regions, including Egypt. Given the prevalence of mosquito-borne diseases and the documented high densities of Culex pipiens in Assiut Governorate, there is a critical need for environmentally friendly mosquito management strategies. This study aimed to identify the morphogenetic and determine the enzymatic potential of native fungal isolates associated with mosquitoes in Assiut Governorate. Eight distinct fungal species were successfully characterized based on their morphological traits and ITS rDNA sequence data. These species were identified as Alternaria tenuissima, Trichoderma hamatum, Purpureocillium lilacinum, Geotrichum candidum, and four Fusarium species (F. oxysporum, F. solani, F. equiseti, and F. incarnatum). The results of enzymatic screening emphasize that twenty-two fungal isolates belonging to eight species had the biochemical machinery substantial for cuticle degeneration, with various levels of phospholipase, lipase, protease, and chitinase activities. The strongest synergistic enzymatic profiles were notably displayed by P. lilacinum and F. equiseti. The extensive morphological and molecular description and enzymatic detection provide crucial promotion for evaluating the potential of these local fungal isolates for future sustainable insect pest management in the specific ecological context of Assiut Governorate.

PMID 42177413
Read full article →
PubMedThe journal of physical chemistry. B2026-05-24

Classical Density Functional Theory Coupled to the SAFT-VR Mie Equation of State: Extension to Associating Fluids.

de Freitas Gonçalves André A, Barros de Souza Nathan N, Fernando Mercier Franco Luis L

We have proposed a theoretical framework that enables the extension of the SAFT-VR Mie Equation of State to inhomogeneous associating fluids, on the basis of the weighted density formalism of classical density functional theory. A Helmholtz energy functional well established in the literature has been incorporated to represent the effect of associating interactions. For water confined in carbon slit-pores of few nanometers, the model predicts density profiles in good agreement with molecular simulations performed in the grand-canonical ensemble. Adsorption and desorption isotherms are obtained for different pore sizes, and capillary condensation and hysteresis are investigated by mapping the grand-potential. The results of our calculations indicate that the most stable curve generally matches one of the curves of GCMC, either adsorption or desorption. Further comparison with another theoretical approach available in the literature indicates similar performance of the models.

PMID 42175948
Read full article →
PubMedScientific reports2026-05-24

Impact of atmospheric electrical charges on ryegrass pollen rupture and sub-pollen particle release.

Venkatesan Sudharsun S, Zare Ali A, Ristovski Zoran D ZD, Alinaghipour Behnaz B et al.

Thunderstorm asthma (TA) is a significant health concern, recorded in 26 instances globally, primarily linked to ryegrass pollen. Existing research has shown that physical forces such as wind and rain can cause pollen to rupture during thunderstorms, creating micronic, inhalable allergen-rich fragments called sub-pollen particles (SPPs). However, little is known about the role of electrical charges in storm clouds, such as those associated with lightning, in triggering pollen rupture. This study presents the first simulation-based evidence that the static electric fields typical of storm clouds (105-870 kV/m) can fragment pollen into SPPs. The results reveal a clear increase in pollen fragmentation and dispersal when exposed to these charges - especially at higher electric field strengths and higher humidity. Under discharge conditions, such as simulated lightning (arcing), fragmentation intensifies, generating abundant, irregularly shaped ruptured pollen particles, as confirmed by scanning electron microscopy. The results identify both static and discharge electrical processes in storm clouds as drivers of pollen rupture, advancing the mechanistic understanding of TA. In the context of climate change-driven increases in severe storm frequency and intensity, this dual-mechanism insight has important implications for forecasting TA risk and mitigating respiratory health impacts.

PMID 42177249
Read full article →
PubMedAmerican journal of ophthalmology2026-05-24

Clinical Features of Corneal Adverse Events Associated with Trastuzumab Botidotin: Payload-Driven Epitheliopathy and Neuropathy.

Zhang Yongyi Y, Tang Gege G, Zhang Jingjie J, Fu Yao Y et al.

HER2-targeted antibody-drug conjugates (ADCs) demonstrate significant efficacy in HER2-mutated or HER2-positive tumors but may cause ocular adverse events (AEs), particularly corneal epitheliopathy and blurred vision. This study aimed to characterize the clinical features of trastuzumab botidotin (a HER2-targeted ADC)-related corneal AEs. Retrospective case series. Eight adult patients (15 eyes) with HER2-mutated or HER2-positive solid tumors treated with trastuzumab botidotin. Assessments included best-corrected visual acuity (BCVA), Ocular Surface Disease Index (OSDI), Schirmer's test, tear break-up time (TBUT), tear meniscus height (TMH), and corneal fluorescein staining (CFS). In vivo confocal microscopy (IVCM) was performed to evaluate cellular structures and confirm lesion characteristics. Corneal AEs associated with trastuzumab botidotin and their clinical features. Corneal AEs occurred in all eight patients. The mean time to visual impairment onset was 37.25 ± 5.90 days after trastuzumab botidotin initiation, with symptom severity peaking at 82.75 ± 14.26 days. OSDI scores increased from 5.73 ± 2.67 at baseline to 65.10 ± 13.26 at peak severity. Trastuzumab botidotin caused dry eye in all patients (n = 8), resulting in reduced Schirmer's test results (from 8.94 ± 1.66 mm to 4.20 ± 1.58 mm), shortened tear break-up time (from 9.63 ± 1.21 s to 3.37 ± 1.61 s), and decreased TMH (from 0.23 ± 0.04 mm to 0.14 ± 0.02 mm). Slit-lamp microscopy and fluorescein staining revealed that trastuzumab botidotin induced distinct corneal epitheliopathy, characterized by pseudomicrocysts, punctate epitheliopathy, diffuse punctate epitheliopathy, and vortex keratopathy. IVCM correlated these findings, showing cyst-like hyperreflective structures in the superficial epithelium, grape-like hyperreflective clusters in wing cells and basal cells, and associated cellular disorganization. IVCM demonstrated neurotoxic damage, characterized by thinning of subbasal nerves, decreased nerve density, and focal discontinuities in the subbasal nerve plexus. Trastuzumab botidotin was associated with visual impairment, corneal epitheliopathy, and nerve damage. Close collaboration between ophthalmologists and oncologists is crucial for early detection of corneal AEs related to ADC therapy, thereby improving clinical outcomes and patient quality of life.

PMID 42176831
Read full article →
PubMedThe Laryngoscope2026-05-23

Longitudinal SNOT-22 Symptom Changes With Sublingual Immunotherapy (SLIT).

Zheng Wynne W, Chang Jolie L JL, Butrymowicz Anna A

Despite widespread use of nasal corticosteroids and oral antihistamines, many patients with allergic rhinitis (AR) have persistent nasal congestion/obstruction and rhinorrhea with associated sleep disturbance and daytime fatigue. Sublingual immunotherapy (SLIT) is associated with reducing symptom burden and medication use. This study aims to evaluate time to clinical benefit and magnitude of first-year benefit after SLIT initiation. Adult AR patients confirmed by skin or IgE testing who initiated allergen-directed SLIT were included. Sinonasal Outcome Test-22 (SNOT-22) and Rhinitis Control Assessment Test (RCAT) surveys were recorded at baseline, 1-6, and 6-12 months after SLIT. Longitudinal changes were assessed using repeated measures analysis of variance and minimal clinically important difference (MCID) thresholds. Exploratory analysis at 3 months was performed for a subset of patients. A total of 43 SLIT patients (mean age 42.1 ± 12.0 years; 40% female) were included and demonstrated significant reductions in total SNOT-22 scores at 1-6 months (-12.1 points; -35%) and 6-12 months (-12.5 points; -36%) (p < 0.01 from baseline). Nasal, sleep, and function SNOT-22 subscores each improved significantly from baseline, whereas the ear/facial subscore did not. MCID for total SNOT-22 was achieved by 54.3% of patients at 1-6 months. RCAT scores improved significantly at 1-6 months and 6-12 months. The proportion of patients with normal SNOT-22 score (≤ 8) increased from 4.7% at baseline to 24.1% at 6-12 months. SLIT was associated with symptom improvement within the first 6 months of therapy based on SNOT-22 and RCAT scores. Symptom score improvements persisted to 12 months, and findings support evidence of early nasal, sleep, and function symptom alleviation with SLIT.

PMID 42174398
Read full article →
PubMedAllergy2026-05-23

Mapping Allergen B- and T-Cell Epitopes: Technological Advances and Their Role in Precision Allergy Therapy.

Møiniche Mark M, Corneliussen Josefine J, Johansen Kristoffer H KH, Ruiz-Carrasco Alexandre A et al.

Allergic diseases arise from aberrant immune recognition of otherwise harmless environmental proteins and are driven by epitope-specific interactions between allergens and the adaptive immune system. Although component-resolved diagnostics have improved molecular characterisation of sensitization, they remain limited to whole-allergen resolution and do not capture the fine specificity and heterogeneity of immune recognition that ultimately determine clinical reactivity, cross-reactivity, and treatment outcomes. Increasing evidence indicates that allergic sensitization, severity, and tolerance are governed by discrete B- and T-cell epitopes rather than entire allergen molecules. This review provides a comprehensive overview of established and emerging technologies for allergen epitope mapping at molecular resolution. For B-cell epitopes, we discuss peptide-based screening approaches, display technologies, deep mutational scanning, structural and biophysical methods, and advances in in silico prediction. For T-cell epitopes, we summarise experimental and computational strategies to identify allergen-derived peptides presented by HLA molecules and recognised by T-cell receptors, highlighting the influence of HLA diversity on individualised immune responses. Finally, we explore the clinical and translational implications of epitope-resolved allergen profiling for next-generation diagnostics, functional cell-based assays, improved risk stratification, cross-reactivity prediction, and the rational design of safer and more precise immunotherapies. Together, these approaches support the development of precision medicine strategies in allergic disease.

PMID 42174388
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about alternaria allergen SLIT